Evidence map›Paper›PMID 34270794›Full record

ArticleInternational journal of cancer2021

Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.

Katie Watts, Christopher Wills, Ayman Madi, Claire Palles, Timothy S Maughan, Richard Kaplan, Nada A Al-Tassan, Rachel Kerr, David Kerr, Victoria Gray and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Katie WattsDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Christopher WillsDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Ayman MadiThe Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK.
Claire PallesInstitute of Cancer and Genomic Sciences, Institute of Biomedical Research, University of Birmingham, Birmingham, UK.
Timothy S MaughanCRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Richard KaplanMRC Clinical Trials Unit, University College of London, London, UK.
Nada A Al-TassanDepartment of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Rachel KerrDepartment of Oncology, University of Oxford, Oxford, UK.
David KerrNuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Victoria GrayDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Hannah WestDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Valentina Escott-PriceInstitute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.
Jeremy P CheadleDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0001-9453-8458
Cardiff University · GBUniversity of Oxford · GBCancer Research UK Clinical Trials Unit · GBClatterbridge Cancer Centre NHS Foundation Trust · GBInstitute of Cancer Research · GBJohn Radcliffe Hospital · GBKing Faisal Specialist Hospital & Research Centre · SAMRC Clinical Trials Unit at UCL · GB

Funding

Cancer Research UK C1298/A8362Medical Research Council G0801418Medical Research Council MC_UU_00004/01Medical Research Council MC_UU_12023/20Medical Research Council MC_UU_12023/25Medical Research Council MC_UU_12023/3Medical Research Council MR/L010305/1Medical Research Council MR/L023784/2Medical Research Council MR/P005748/1Medical Research Council MR/T033371/1Medical Research Council MR/T04604X/1
6 · The paper itself

Abstract

Chemotherapies administered at normal therapeutic dosages can cause significant side-effects and may result in early treatment discontinuation. Inter-individual variation in toxicity highlights the need for biomarkers to personalise treatment. We sought to identify such biomarkers by conducting 40 genome-wide association studies, together with gene and gene set analyses, for any toxicity and 10 individual toxicities in 1800 patients with advanced colorectal cancer treated with oxaliplatin and fluoropyrimidine chemotherapy ± cetuximab from the MRC COIN and COIN-B trials (385 patients received FOLFOX, 360 FOLFOX + cetuximab, 707 XELOX and 348 XELOX + cetuximab). Single nucleotide polymorphisms (SNPs), genes and gene sets that reached genome-wide or suggestive significance were validated in independent patient groups. We found that MROH5 was significantly associated with neutropenia in MAGMA gene analyses in patients treated with XELOX (P = 6.6 × 10

Indexed as

Polymorphism, Single NucleotideAdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCetuximabColorectal NeoplasmsDiarrheaDrug-Related Side Effects and Adverse ReactionsFemaleFluorouracilGenome-Wide Association StudyGenotypeHumansMaleMiddle AgedCapecitabineCetuximabFluorouracilOxaliplatinribosomal protein L17Ribosomal ProteinsSCAF4 protein, humanSerine-Arginine Splicing Factorschemotherapycolorectal cancerGWAStoxicity

Identifiers

PMID34270794
PMCPMC7616640
OpenAlexW3182157089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.